Abstract
Plasma-derived HB vaccine which is inacivated HBsAg purifeied from plasma of HBV carriers, has been aplied the clinical use in Japan, Plasma-derived vaccine has the disadvantage as follows: 1) It is limmited to obtain the raw materials which come from plasma of HBV carriers. 2) This vaccine can not be completely indeniable the comtamination of unknown viruses. 3) It is necessary chimpanzees for its safty test.
Yeast- and cell-derived recombinant HB vaccines are now studying, as the second generation vaccine.
Three dose injection (0, 1, 6 month) of plasma-derived HB vaccine (one dose: 20 mcg in adult, 10 mcg in infant) is needed for the prevention of HBV infection. When exposed HBV, administration of immunoglobulin containng high titier anti-HBs (HBIG) and HB vaccine simultaneously is necessary. For the control of HBV carrier, the prevention of HBV infection against babies from HBeAg positive mothers started the beginning of this year in Japan.
